

Interventional Urology update


Coloplast Capital Markets Day 2018


Steffen Eichner Hovard, Senior Vice President, Interventional Urology

Coloplast Group – Ostomy Care / Continence Care / Wound & Skin Care / Urology Care



Interventional Urology is a global division that outpaces the market with its comprehensive portfolio of solutions







We provide solutions that substantially change patients' urological conditions, a space called Interventional Urology

What is Interventional Urology

Patient treatment pathway

Jrological Conditions

Adjust

Diet Exercise OTC Products Monitoring



Prescribe

Rx regimen
Lifestyle modifications
Monitoring



Manage

Chronic or temporary devices
Therapeutic aids



Intervene ants, intervention

Implants, interventional diagnostics and procedures







The market continues to grow and witness increased price and regulatory pressures and new technology entrants

Healthcare and Market Trends

Patients



- Aging global population
- Lifestyles driving disease prevalence
- Demand growing for minimally invasive treatments

Markets



- Improved healthcare in developing markets
- Multiple existing lowcost suppliers
- Reimbursement and purchasing power growing

Customers



- Decision power shift to non-clinical buyers
- Customer price pressure initiatives
- Demand for demonstrated economic benefit

Regulations



- Heightened regulations globally
- Increased demand for proof and outcomes

Competitors



- New competitor and technology entrants
- Competitor M&A and consolidation
- Driving growth in Emerging Markets
- Focus on hospital contracting




Interventional Urology is a DKK 12bn market growing 3-5% annually

	Business Area Market Dynamics	Market Size (DKKbn)	Market growth
Endourology	Portfolio breadth increasingly valuedSingle-use visualization significant opportunity	~4	~5%
Men's Health	 Penile implant market responding to patient awareness Opportunities in portfolio expansion and innovation 	~3	~4%
Women's Health	 Need for prolapse and incontinence options remains Regulatory and legal environment normalizing 	~3	~3%
Specialty Interventions	 Lower cost competitors entering MDR* challenges mid-size companies 	~2	~3%

Source: Coloplast estimates
*EU Medical Device Regulation



We have successfully delivered on our strategy launched in 2014 and built a profitable, sustainable business






Source: Coloplast



Innovative products have contributed to our growth and laid the foundation for our portfolio strategy



Resulting strategy around Innovation

Differentiated solutions to simplify procedures and improve outcomes



Leveraging commercial organization focus and clinical depth



Innovating for future site of care



Elevating existing portfolio



Augmenting portfolio to serve near adjacencies



Future value creation stems from efficiently delivered, differentiated solutions, and personal, trusted expertise



Proven Solutions

Expand and

strengthen our portfolio & impact



Trusted Expertise

Provide our deep expertise to Healthcare Professionals



Efficient Operations

Transform operational footprint and processes




Great
Employees
Invest in and


develop our organization






Our continued growth is driven by investments in commercial expansion, innovation and new adjacencies





Source: Coloplast estimates

By executing on our strategic priorities we will scale the business over time while sustaining strong profitability





Our mission

Making life easier for people with intimate healthcare needs

Our values

Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us

Our vision

Setting the global standard for listening and responding

